BDSX
BEARISH
$11.74
Live
Biodesix, Inc. · NASDAQ
Target $32.5
(+176.8%)
$3.44
52W Range
$21.8
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$93.92M
P/E
N/A
ROE
-302.6%
Profit margin
-49.3%
Debt/Equity
N/A
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
68%
The company exhibits a critically weak financial health profile with a Piotroski F-Score of just 1/9, indicating severe fundamental deterioration. Despite strong revenue growth and a bullish analyst recommendation, persistent unprofitability, negative valuation multiples, and bearish insider activity raise substantial concerns. The stock's recent sharp price rebound contrasts with a 5-year return of -97.8%, reflecting extreme volatility and lack of long-term value creation. While gross margins are healthy at 79.82%, the negative ROE of -302.55% and negative price-to-book ratio highlight structural profitability and equity issues.
Key Strengths
Strong year-over-year revenue growth of 19.90%
High gross margin of 79.82% indicating pricing power or low cost of goods
Improving earnings trend with YoY EPS growth of +17.1% and Q/Q EPS growth of +27.5%
Current and quick ratios above 1.6, suggesting short-term liquidity is manageable
Bullish analyst consensus with a strong_buy rating and high target price of $32.50
Key Risks
Critically low Piotroski F-Score of 1/9 signaling weak financial health
Negative profit margin (-49.31%) and negative ROE (-302.55%) indicating deep unprofitability
Negative Forward P/E and Price/Book ratios make traditional valuation unreliable
Bearish insider sentiment with 10 sell transactions and no buys in the last 6 months
Extreme volatility and massive 5-year price decline of -97.8% despite recent rebound
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
21
Weak
15
58
22
10
0
AI Verdict
High-risk speculative position with unproven profitability and conflicting signals
Key drivers: Low Piotroski F-Score, Negative earnings and valuation metrics, Bullish analyst target, Recent price momentum, Bearish insider activity
Confidence
70%
Value
15/100
Ref P/E, PEG, Graham Number
Positives
- Price/Sales ratio of 1.17 is moderate for a growth-stage healthcare company
Watchpoints
- Forward P/E of -53.36 indicates negative earnings
- Price/Book of -54.35 invalidates book value as a floor
- No Graham Number due to unprofitability
Future
58/100
Ref Growth rates
Positives
- Revenue growth of 19.90% YoY
- Q/Q EPS growth of +27.5%
- Analyst target implies 177% upside
Watchpoints
- Earnings growth (YoY) is N/A, suggesting inconsistency
- No PEG ratio due to unreliable earnings
Past
22/100
Ref Historical trends
Positives
- Some quarters show positive earnings surprises (e.g., +23% in Nov 2025)
Watchpoints
- Frequent earnings misses (only 1 beat in last 4 quarters)
- Historical EPS volatility with large negative values
- 5-year price return of -97.8% indicates prolonged underperformance
Health
10/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current ratio of 1.84 and quick ratio of 1.61 indicate short-term liquidity
Watchpoints
- Piotroski F-Score of 1/9 indicates severe financial weakness
- No Altman Z-Score reported, but negative equity metrics suggest distress risk
- ROA of -21.12% and negative ROIC
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- Dividend Strength of 0/100
- No dividend yield or payout history
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$11.74
Analyst Target
$32.5
Upside/Downside
+176.8%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for BDSX and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
BDSX
Biodesix, Inc.
Primary
|
-97.8% | -75.2% | -34.9% | +31.6% | +72.1% | +49.0% |
|
MXCT
MaxCyte, Inc.
Peer
|
-94.8% | -83.5% | -66.1% | -46.6% | +8.7% | +24.1% |
|
WW
WW International, Inc.
Peer
|
-65.6% | -65.6% | -65.6% | -69.4% | -46.6% | -12.9% |
|
SERA
Sera Prognostics, Inc.
Peer
|
-80.7% | -29.7% | -32.4% | -28.1% | +20.4% | +16.8% |
|
STIM
Neuronetics, Inc.
Peer
|
-87.2% | -31.4% | -62.2% | -47.2% | +5.2% | +5.2% |
BDS
Biodesix, Inc.
Primary
5Y
-97.8%
3Y
-75.2%
1Y
-34.9%
6M
+31.6%
1M
+72.1%
1W
+49.0%
MXC
MaxCyte, Inc.
Peer
5Y
-94.8%
3Y
-83.5%
1Y
-66.1%
6M
-46.6%
1M
+8.7%
1W
+24.1%
WW
WW International, Inc.
Peer
5Y
-65.6%
3Y
-65.6%
1Y
-65.6%
6M
-69.4%
1M
-46.6%
1W
-12.9%
SER
Sera Prognostics, Inc.
Peer
5Y
-80.7%
3Y
-29.7%
1Y
-32.4%
6M
-28.1%
1M
+20.4%
1W
+16.8%
STI
Neuronetics, Inc.
Peer
5Y
-87.2%
3Y
-31.4%
1Y
-62.2%
6M
-47.2%
1M
+5.2%
1W
+5.2%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-53.36
PEG Ratio
N/A
P/B Ratio
-54.35
P/S Ratio
1.17
EV/Revenue
1.89
EV/EBITDA
-5.68
Market Cap
$93.92M
Profitability
Profit margins and return metrics
Profit Margin
-49.31%
Operating Margin
-32.36%
Gross Margin
79.82%
ROE
-302.55%
ROA
-21.12%
Growth
Revenue and earnings growth rates
Revenue Growth
+19.9%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
N/A
Current Ratio
1.84
Good
Quick Ratio
1.61
Excellent
Cash/Share
$2.09
Quarterly Earnings History
EPS performance vs analyst estimates
2026-03-03
$N/A
2025-11-03
$-1.16
+23.0% surprise
2025-08-07
$-1.6
-17.1% surprise
2025-05-13
$-1.6
-14.3% surprise
Healthcare Sector Comparison
Comparing BDSX against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
Return on Equity (ROE)
-302.55%
This Stock
vs
-88.14%
Sector Avg
+243.3%
(Excellent)
Profit Margin
-49.31%
This Stock
vs
-16.28%
Sector Avg
+202.9%
(Superior)
Revenue Growth
19.9%
This Stock
vs
124.04%
Sector Avg
-84.0%
(Slower)
Current Ratio
1.84
This Stock
vs
4.47
Sector Avg
-58.9%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
BDSX
Biodesix, Inc.
|
BEARISH | $93.92M | - | -302.6% | -49.3% | $11.74 | |
|
MXCT
MaxCyte, Inc.
|
BEARISH | $94.19M | - | -23.6% | -135.1% | $0.88 | Compare |
|
WW
WW International, Inc.
|
BEARISH | $92.87M | 1.23 | -% | 148.6% | $9.29 | Compare |
|
SERA
Sera Prognostics, Inc.
|
BEARISH | $90.03M | - | -51.8% | -% | $2.3 | Compare |
|
STIM
Neuronetics, Inc.
|
BEARISH | $98.8M | - | -134.9% | -26.1% | $1.42 | Compare |
BDSX
Biodesix, Inc.
BEARISH
Mkt Cap
$94M
P/E
-
ROE
-302.6%
Price
$11.74
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-16 | HUTTON SCOTT | Chief Executive Officer | Sale | 970 | $7,905 |
| 2026-01-16 | O'KANE KIERAN | Officer | Sale | 298 | $2,428 |
| 2026-01-16 | COWIE ROBIN HARPER | Chief Financial Officer | Sale | 298 | $2,428 |
| 2026-01-16 | PESTANO GARY ANTHONY | Officer | Sale | 298 | $2,428 |
| 2026-01-16 | VAZQUEZ CHRISTOPHER | Officer | Sale | 83 | $676 |
| 2026-01-15 | HUTTON SCOTT | Chief Executive Officer | Stock Award | 2,633 | - |
| 2026-01-15 | O'KANE KIERAN | Officer | Stock Award | 805 | - |
| 2026-01-15 | COWIE ROBIN HARPER | Chief Financial Officer | Stock Award | 805 | - |
| 2026-01-15 | PESTANO GARY ANTHONY | Officer | Stock Award | 805 | - |
| 2026-01-15 | VAZQUEZ CHRISTOPHER | Officer | Stock Award | 219 | - |
| 2026-01-05 | PATIENCE JOHN | Chairman of the Board | Stock Award | 1,143 | - |
| 2025-11-10 | HUTTON SCOTT | Chief Executive Officer | Sale | 189 | $1,440 |
| 2025-11-10 | O'KANE KIERAN | Officer | Sale | 25 | $190 |
| 2025-11-10 | COWIE ROBIN HARPER | Chief Financial Officer | Sale | 50 | $381 |
| 2025-11-10 | PESTANO GARY ANTHONY | Officer | Sale | 23 | $175 |
HUTTON SCOTT
Chief Executive Officer
2026-01-16
970 shares
·
$7,905
O'KANE KIERAN
Officer
2026-01-16
298 shares
·
$2,428
COWIE ROBIN HARPER
Chief Financial Officer
2026-01-16
298 shares
·
$2,428
PESTANO GARY ANTHONY
Officer
2026-01-16
298 shares
·
$2,428
VAZQUEZ CHRISTOPHER
Officer
2026-01-16
83 shares
·
$676
HUTTON SCOTT
Chief Executive Officer
2026-01-15
2,633 shares
O'KANE KIERAN
Officer
2026-01-15
805 shares
COWIE ROBIN HARPER
Chief Financial Officer
2026-01-15
805 shares
PESTANO GARY ANTHONY
Officer
2026-01-15
805 shares
VAZQUEZ CHRISTOPHER
Officer
2026-01-15
219 shares
PATIENCE JOHN
Chairman of the Board
2026-01-05
1,143 shares
HUTTON SCOTT
Chief Executive Officer
2025-11-10
189 shares
·
$1,440
O'KANE KIERAN
Officer
2025-11-10
25 shares
·
$190
COWIE ROBIN HARPER
Chief Financial Officer
2025-11-10
50 shares
·
$381
PESTANO GARY ANTHONY
Officer
2025-11-10
23 shares
·
$175
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
4 analysts
Canaccord Genuity
2025-09-19
Buy
Buy
Past News Coverage
Recent headlines mentioning BDSX from our newsroom.
Newest → oldest
No matching news yet.